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Background: Autoantibodies against 
nodal and paranodal proteins, particularly 
anti-neurofascin (NF) antibodies, have 
been recently described in demyelinating 
disorders of the central and peripheral 
nervous system. There is an unmet need for 
further characterization of anti-NF associated 
demyelinating diseases. We describe the 
patients with anti-NF antibodies, and attempt 
to identify features that might guide clinicians 
to check for them.
Methods: This is a retrospective chart review 
Nebraska Medical Center Multiple Sclerosis 
Clinic who tested positive for serum anti-NF 
antibodies by western blot.
Results:
female to male ratio was 4:1, and the median 
age at presentation was 60 years (range: 
56-70). Clinical presentations included 
incomplete transverse myelitis (n=2), 
progressive myelopathy (n=1), recurrent 
symmetric polyneuropathy (n=1), and 
Atypical features prompting further workup 
included co-existing upper and lower motor 
neuron features, older age at presentation 
anti-NF antibody panel was positive for the 
Conclusions: Our case-series suggests that 
anti-NF antibodies are more commonly 
detected in the older populations and women. 
The clinical phenotype is pleiotropic. Atypical 
prompted further workup. Larger studies 
are needed to assess the impact of anti-NF 
antibodies on long-term clinical outcomes and 
their associated therapeutic implications. 
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Background: The objective of the study is 
to describe the clinical characteristics and 
identify unique features associated with 
antibody-positive autoimmune encephalitis 
(AE). 
Methods: Charts of children aged below 
18-years diagnosed with AE between 2005 
and 2020 were reviewed. Demographics, 
clinical characteristics, laboratory, imaging, 
neurological-sequalae were collected.
Results: Among 53 AE cases, 19 had serum 
or CSF antibodies. Among antibody-positive 
AE patients, there were 9 (47%) male and 10 
(53%) female patients of whom; 10 (52.6%) 
had anti-NMDAR-antibodies, 5 (26%) anti-
GAD65-antibodies. Clinical presentation 
included neuropsychiatric symptoms (68.4%), 
altered mental status (63%), movement 
disorders (57.9%), new-onset seizures 
epilepticus (10.5%) and sleep dysfunction 
admission and 9 (47.3%) experienced 
was abnormal with T2 hyperintensities in 
13 patients (31.5%) - 3 in parietal lobe, 2 in 
temporal lobe and 2 in frontal lobe. Seven 
Nine patients (47.3%) had CSF pleocytosis 
and protein was normal in all patients. Acute 
management consisted of several different 
combination regimens including intravenous 
steroids (89%), intravenous immunoglobulin 
exchange (PLEX) (10.5%). Maintenance 
(36.8%) and 1 PLEX. Six patients (31.5%) 
attained complete remission and one patient 
underwent excision of ovarian teratoma. 
Long term sequalae included neurocognitive 
disturbances (52.6%), epilepsy (31.5%) and 
movement disorders (5%).
Conclusion: The most frequent presentation 
of AE in our cohort was neuropsychiatric 
disturbances, followed by altered mental 
status. Given diverse clinical presentations, 
one should maintain broad differential 
diagnosis when evaluating pediatric  
patients with subacute onset neurological 
symptoms. 
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Background: A complete understanding 
of factors driving the increased all-cause 
mortality risk in patients with gout is lacking. 
The purpose of this study was to examine 
risk factors associated with mortality among 
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Methods: We performed a retrospective 
cohort study, identifying patients with gout 
followed from the index date until death or 
censoring. Potential predictors of mortality 
Multivariable Cox regression models were 
constructed to identify independent predictors 
of all-cause mortality.
Results: 
4,250,477 patient-years of follow-up, there 
were 246,291 deaths. Multivariable adjusted 
associations with all-cause mortality are 
shown in Table 1. Risk factors associated 
with increased mortality risk included 
male sex, older age, Black non-Hispanic 
race, comorbidities, diuretic, opioid, ULT, 
colchicine, and steroid use. Factors associated 
with a lower risk of all-cause mortality 
included white Hispanic, black Hispanic, and 
Conclusion: 
multiple risk factors for mortality in veterans 
with gout with the strongest risk factors 
and cancer, as well as the use of steroids 
and opioids. Mechanisms underpinning 
associations between select medication use 
and survival will require additional study 
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Background: Androgen receptor (AR) 
malignant gliomas, suggesting that AR plays 
an important role in tumor carcinogenesis. 
overexpression remains largely to be explored.
Methods: AR gene expression at the levels of 
mRNA, protein expression, and clinical data 
were obtained from the Cancer Genome Atlas 
(TCGA) and Chinese Glioma Genome Atlas 
(CGGA) databases. AR expression levels 
were compared across gliomas of different 
histopathologic and molecular subtypes. 
Lastly, Kaplan-Meier survival analyses in 
patients with different AR expression levels 
were investigated for the potential prognostic 
values of AR.
Results: Compared to normal brain tissue, 
higher AR mRNA expression (p < .01). 
Furthermore, AR mRNA expression was more 
prominent in higher grade disease, regardless 
of histopathologic and molecular subtypes 
(p < 0.01). Similarly, at the protein level, AR 
protein was more abundant in GBM than in 
(p <0.0001). This was corroborated by a linear 
association between AR mRNA and protein 
expression (r = 0.65, p < 0.001). Finally, 
in LGG, both high AR gene and protein 
worse overall survival. Five-year overall 
survival for patients with LGG with high AR 
Table 1.
Patient characteristics associated with all-cause mortality in veterans with gout.
Characteristic
Age, Years 1.06 (1.06, 1.06)









0.81 (0.78, 0.83) 
Referent 
0.78 (0.69, 0.89) 
1.06 (1.04, 1.07) 
0.62 (0.59, 0.66) 
1.07 (1.04, 1.09) 
1.95 (1.93, 1.97)
Service Connected Condition 0.84 (0.83, 0.85)
Urban Residence (vs. Rural) 1.02 (1.02, 1.03)
VHA Enrollment Duration, Years 0.95 (0.95, 0.95)
Health Factors & Comorbidities
Body Mass Index
<20 kg/m2
20 to <25 kg/m2






Myocardial infarction or atherosclerosis, %

















Diuretic Use 1.37 (1.36, 1.39)
ULT Use (Allopurinol, Febuxostat, Probenecid, 
Pegloticase)
1.04 (1.03, 1.05)
NSAID Use 0.87 (0.86, 0.88)
Steroid Use 1.15 (1.13, 1.16)
Colchicine Use 1.08 (1.07, 1.09)
Opioid Use 1.17 (1.16, 1.19)
0.99 (0.98, 1.00)
*All variables included in multivariable model are shown in the table
Abbreviations: VHA, Veterans Health Administration; ULT, urate lowering therapy
